BioLineRx Ltd. (TLV:BLRX)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 60.05M |
| Revenue (ttm) | 58.12M |
| Net Income (ttm) | -26.35M |
| Shares Out | 2.61B |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 976,694 |
| Average Volume | 5,057,130 |
| Open | 2.300 |
| Previous Close | 2.300 |
| Day's Range | 2.200 - 2.300 |
| 52-Week Range | 1.400 - 14.500 |
| Beta | 0.91 |
| RSI | 64.78 |
| Earnings Date | Nov 20, 2025 |
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin les... [Read more]
Financial Performance
In 2024, BioLineRx's revenue was $28.94 million, an increase of 502.92% compared to the previous year's $4.80 million. Losses were -$9.22 million, -84.79% less than in 2023.
Financial numbers in USD Financial StatementsNews
BioLineRx Ltd. (BLRX) Investor Call (Transcript)
BioLineRx and Hemispherian launch a joint venture to develop GLIX1, a first-in-class
BioLineRx Ltd. - Special Call
BioLineRx (BLRX) and Hemispherian Collaborate on Innovative Cancer Therapy
BioLineRx (BLRX) and Hemispherian Collaborate on Innovative Cancer Therapy
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - - Glioblas...
BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript
BioLineRx GAAP EPS of $0.00, revenue of $5.39M
BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- Provides updated and extended cash...
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE: STG) is likely to report earnings for its second quarter. • TORM (NASDAQ: TRMD) is expected to report quarterly earnings at $0.57 per...
BioLineRx Q2 2025 Earnings Preview
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd.
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
BioLineRx Ltd's BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 Am...
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
BioLineRx Ltd’s (NASDAQ: BLRX) poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at ...
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
- 4 of 11 PDAC patients in the pilot phase remained progression free at over one year - Poster presentation on Saturday, May 31 st TEL AVIV, Israel , May 30, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDA...
BioLineRx projects cash runway into H2 2026 while advancing PDAC pipeline and APHEXDA royalty growth
BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript
BioLineRx GAAP EPS of $0.00 beats by $0.95, revenue of $0.26M misses by $1.22M
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4METPANC Pha...
Earnings Scheduled For May 27, 2025
Companies Reporting Before The Bell • Bank of Nova Scotia (NYSE: BNS) is projected to report quarterly earnings at $1.57 per share on revenue of $9.02 billion. • Evaxion (NASDAQ: EVAX) is likely to ...
A Look at BioLine Rx's Upcoming Earnings Report
BioLine Rx (NASDAQ: BLRX) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-27. Here's a quick overview of what investors should know before the release. Analysts are estimating th...
BioLineRx Q1 2025 Earnings Preview
BioLineRx (BLRX) Q1 earnings set for May 27 with EPS estimate at -$1.06 & revenue down 78.4% Y/Y.
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 20, 2025 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chie...
BioLineRx GAAP EPS of -$0.01, revenue of $28.94M
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. f...